BELITE BIO INC ADS news, videos and press releases
For more news please use our advanced search feature.
BELITE BIO INC ADS - More news...
BELITE BIO INC ADS - More news...
- Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
- Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
- Belite Bio to Participate in the Leerink Partners Global Healthcare Conference
- Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects
- Belite Bio Announces Registered Direct Offering of $15 Million
- Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
- Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
- Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds
- Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
- Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit
- Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease
- Belite Bio to Participate in Three Upcoming Investor Conferences
- Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
- Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
- Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
- Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results
- Belite Bio to Present at the JonesHealthcare Seaside Summit
- Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
- Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
- Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
- Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
- Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
- Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant
- Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
- Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
- Belite Bio Announces $25 Million Registered Direct Offering
- Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
- Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
- Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
